Park Young-cheol: Transitional Toxicology Consulting
How do you get the most and most toxic tests done? How can we get into the global market with drug development? The history of the domestic CAP-based toxic test officially reaches over 25 years, and since then drug multiplicity has rapidly varied with the advent of biodrugs. Within a few years, the bio-drug development platform has expanded to predict that synthetic drugs and market share will be equal. The following kind of drug multitasky, the physics and chemical properties of the candidate drug are considered important by the general public. A small molecule synthetic drug, vaccines and the Toxoid vaccines, and a plasma derivative, or a protein-to-peptide cure, or anti-degradable cure, and an enzyme therapy, or an enzyme-tompic therapy, and the drug compound: antibodies-y drugs, multiple-temple antibodies, and multi-cell antibodies, as well as nano-resistant antibodies, which are used to provide a lethal cure for antibodies and gene cells, or genetic stem cells, and advanced drugs for the drug. Depending on the difference in drug mode, we have a subpoena of one toxic test, the selection of two receptors, three toxic and effective tests at the same time, four injections of importance, five animal testing ethics and threeR considerations, six clinical security safety options, and a successful INDIdging approach.
Korean title: 전환기 독성시험 컨설팅
Korean author: 박영철
Korean publisher: 한국학술정보
ISBN-13: 9791169838177
